Less commonly used antiepileptic drugs

Wyllie's Treatment of Epilepsy: Principles and Practice: Fifth Edition

Volumn , Issue , 2012, Pages 779-789

  Uthman, Basim M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973429097     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (143)

1. Scott Levin's PPDA, MAT. February 1999.
2. Merritt HH, Putnam TJ. A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatry. 1938;39:1003-1015.
3. Putnam TJ, Merritt HH. Experimental determination of anticonvulsant properties of some phenyl derivatives. Science. 1937;85:525-526.
4. Merritt HH, Putnam TJ. Sodium diphenylhydantoinate in treatment of convulsive disorders. J Am Med Assoc. 1938;111:1068-1073.
5. Kupferberg HJ. Other hydantoins: mephenytoin and ethotoin. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989:257-266.
6. Schwade ED, Richards RK, Everett GM. Peganone, a new anticonvulsant drug. Dis Nerv Syst. 1956;17:155-158.
7. Carter CA, Helms RA, Boehm R. Ethotoin in seizures of childhood and adolescence. Neurology. 1984;34:791-795.
8. Biton V, Gates JR, Ritter FJ, et al. Adjunctive therapy for intractable epilepsy with ethotoin. Epilepsia. 1990;31:433-437.
9. Finnell RH, Dilibert JH. Hydantoin-induced teratogenesis: are arene oxide intermediates really responsible? Helv Paediatr Acta. 1983;38: 171-177.
10. Zablen M, Brand N. Cleft lip and palate with the anticonvulsant ethotoin. N Engl J Med. 1977;297:1404.
11. Wilder BJ, Bruni J. Seizure Disorders: A Pharmacological Approach to Treatment. New York: Raven Press; 1981.
12. Glazko AJ, Dill WA. Other succinimides: methsuximide and phensuximide. In: Woodbury DM, Penry JK, Schmidt RP, eds. Antiepileptic Drugs. New York: Raven Press; 1972:455-464.
13. Porter RJ, Penry JK, Lacy IR, et al. Plasma concentrations of phensuximide, methsuximide and their metabolites in relation to clinical efficacy. Neurology. 1979;29:1509-1513.
14. Strong JM, Abe R, Gibbs EL, et al. Plasma levels of methsuximide and N-desmethylmethsuximide during methsuximide therapy. Neurology. 1974;24:250-255.
15. Wilder BJ, Buchanan RB. Methsuximide for refractory complex partial seizures. Neurology. 1981;31:741-744.
16. Browne TR, Feldman RG, Buchanan RA, et al. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983;33:414-418.
17. Coroba EF, Strobos RRJ. N-methyl-2-methylphenyl-succinimide, in psychomotor epilepsy. Dis Nerv Syst. 1956;17:383-385.
18. Aird RB, Woodbury DM. The Management of Epilepsy. Springfield, IL: Charles C Thomas; 1974.
19. French EG, Rey-Bellet J, Lennox WG. Methsuximide in psychomotor and petit mal seizures. N Engl J Med. 1958;253:892-894.
20. Livingston S, Pauli L. Celontin in the treatment of epilepsy. Pediatrics. 1957;19:614-618.
21. Zimmerman FT, Burgemeister BB. Use of N-methyl-a,-a-methylphenylsuccinimide in the treatment of petit mal epilepsy. Arch Neurol Psychiatry. 1954;72:720-725.
22. Uthman BM, Wilder BJ. Methsuximide. In: Kutt H, Resor SR, eds. Medical Treatment of Epilepsy. New York: Marcel Dekker; 1991: 379-384.
23. Sigler M, Strassburg HM, Boenigk HE. Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood. Seizure. 2001;10: 120-124.
24. Tennison MB, Greenwood RS, Miles MV. Methsuximide for intractable childhood seizures. Pediatrics. 1991;87:186-189.
25. Carter CH, Maley MC. Use of Celontin in the treatment of mixed epilepsy. Neurology. 1957;7:483-484.
26. Dow RW, McFarlane JP, Stevens JR. Celontin in patients with refractory epilepsy. Neurology. 1958;8:201-204.
27. Scholl ML, Abbott JA, Schwab RS. Celontin-a new anticonvulsant. Epilepsia. 1959;1:105-109.
28. Zimmerman FT. N-methyl-a,a-methylphenylsuccinimide in psychomotor epilepsy treatment. Arch Neurol Psychiatry. 1956;76:65-71.
29. Livingston S, Eisner V, Pauli L. Minor motor epilepsy: diagnosis, treatment and prognosis. Pediatrics. 1958;21:916-928.
30. Rabe F. Celontin (Petinutin)-a contribution to the differential therapy of epilepsy [German]. Nervenarzt. 1960;7:306-312.
31. Brenner RP, Seelinger DF. Drawing-induced seizures. Arch Neurol. 1979;36:515-516.
32. Hurst DL. Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996;5:47-50.
33. Rambeck B. Pharmacological interactions of methsuximide with phenobarbital and phenytoin in hospitalized epileptic patients. Epilepsia. 1979;20:147-156.
34. Eichelbaum M, Kothe KW, Hoffmann F, et al. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther. 1979;26:366-371.
35. May T, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit. 1999;21:175-181.
36. Besag FM, Berry DJ, Vasey M. Methsuximide reduces valproic acid serum levels. Ther Drug Monit. 2001;23:694-697.
37. Mataringa MI, May TW, Rambeck B. Does lamotrigine influence valproate concentrations? Ther Drug Monit. 2002;24:631-636.
38. Besag FM. Methsuximide lower lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000;41:624-627.
39. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit. 2002;24:366-374.
40. Dooley J, Camfield P, Buckley D, et al. Methsuximide-induced movement disorder. Pediatrics. 1991;88:1291-1292.
41. Karch SB. Methsuximide overdose: delayed onset of profound coma. J Am Med Assoc. 1973;223:1463-1465.
42. Baehler RW, Work J, Smith W, et al. Charcoal hemoperfusion in the therapy for methsuximide and phenytoin overdose. Arch Intern Med. 1980;140:1466-1468.
43. Hauptman A. Luminal bei Epilepsie. Munch Med Wochenschr. 1912;59: 1907-1909.
44. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med. 1985;313:145-151.
45. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. N Engl J Med. 1990;322:364-369.
46. Goldberg RN, Moscoso P, Bauer CR, et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. J Pediatr. 1986;109:851-856.
47. Kuban KCK, Krishnamoorthy KS, Littlewood Teele R, et al. Neonatal intracranial hemorrhage and phenobarbital. Pediatrics. 1986;77:443-450.
48. Painter MJ. How to use phenobarbital. In: Morselli PL, Pippenger CE, Penry JK, eds. Antiepileptic Drug Therapy in Pediatrics. New York: Raven Press; 1983:245-250.
49. Wallin A, Boreus LO. Phenobarbital prophylaxis for hyperbilirubinemia in preterm infants: a controlled study of bilirubin disappearance and infant behavior. Acta Pediatr Scand. 1984;73:488-497.
50. Pritchard JW. Phenobarbital mechanisms of action. In: Woodbury D, Penry JK, Pippenger CE, eds. Antiepileptic Drugs. 2nd ed. New York: Raven Press; 1982:1332-1335.
51. Hooper WD, Kunze HE, Eadie MJ. Qualitative and quantitative studies of methylphenobarbital metabolism in man. Drug Metab. 1981;9:381-385.
52. Craig CR, Shideman FE. Metabolism and anticonvulsant properties of mephobarbital and phenobarbital in rats. J Pharmacol Exp Ther. 1971; 176:35-41.
53. Buch H, Knabe J, Buzello W, et al. Stereospecificity of anaesthetic activity, distribution, inactivation and protein binding of the optical antipodes of two N-methylated barbiturates. J Pharmacol Exp Ther. 1970;176:709-716.
54. Smith JA, Waddell WJ, Butler TC. Demethylation of N-methyl derivatives of barbituric acid, hydantoin and 2,4-oxazolidinedione by rat liver microsomes. Life Sci. 1963;7:486-492.
55. Butler TC, Mahaffee D, Mahaffee C. The role of the liver in the metabolic disposition of mephobarbital. J Pharmacol Exp Ther. 1952;106:364-369.
56. Kobayashi K, Morita J, Chiba K, et al. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of Rand S-mephobarbital in humans. Pharmacogenetics. 2004;14(8):549-556.
57. Hooper WD, Kunze HE, Eadie MJ. Pharmacokinetics and bioavailability of methylphenobarbital in man. Ther Drug Monit. 1981;3:39-44.
58. Blum E. Die Bekanfung epileptischer Anfalle und iher Folgeer Scheinungen mit Prominal. Dtsch Med Wochenschr. 1932;58:230-236.
59. Eadie MJ. Other barbiturates: methyl-phenobarbital and metharbital. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989:357-378.
60. Kupferberg HJ, Longacre-Shaw J. Mephobarbital and phenobarbital plasma concentrations in epileptic patients treated with mephobarbital. Ther Drug Monit. 1979;1:117-122.
61. Hutt SJ, Jackson PM, Belsham A, et al. Perceptual-motor behavior in relation to blood phenobarbital level: a preliminary report. Dev Med Child Neurol. 1968;10:626-632.
62. Camfield C. Clinical Trials of Phenobarbital. Presented at the NIH Consensus Development Conference on Febrile Seizures; May 19-21, 1980; Bethesda, MD.
63. McLeod CM, Dekaban AS, Hunt E. Memory impairment in epileptic patients: selective effects of phenobarbital concentrations. Science. 1978; 202:1102-1104.
64. Willis J, Nelson A, Black FW, et al. Barbiturate anticonvulsants: a neuropsychological and quantitative electroencephalographic study. J Child Neurol. 1997;12:169-171.
65. Bergstrom WH, Carzoli RF, Lombroso C, et al. Observations on metabolic and clinical effects of carbonic anhydrase inhibitors in epileptics. Am J Dis Child. 1952;84:771-772.
66. Ansell B, Clarke E. Acetazolamide in treatment of epilepsy. Br Med J. 1956;1:650-661.
67. Forsythe WI, Owens JR, Toothill C. Effectiveness of acetazolamide in the treatment of carbamazepine-resistant epilepsy in children. Dev Med Child Neurol. 1981;23:761-769.
68. Golla FL, Sessions HR. Control of petit mal by acetazolamide. J Ment Sci. 1957;103:214-217.
69. Lombroso CT, Davidson DT Jr, Gross-Bianchi ML. Further evaluation of acetazolamide (Diamox) in treatment of epilepsy. J Am Med Assoc. 1956;160:268-272.
70. Millichap JG. Anticonvulsant action of Diamox in children. Neurology. 1956;6:552-559.
71. Maren TH, Mayer E, Wadsworth BC. Carbonic anhydrase inhibition, I: the pharmacology of Diamox (2-acetylamino-1,3,4-thiadiazole-5sulfonamide). Bull Johns Hopkins Hosp. 1954;95:199-243.
72. Millichap JG, Woodbury DM, Goodman LS. Mechanism of the anticonvulsant action of acetazolamide, a carbonic anhydrase inhibitor. J Pharmacol Exp Ther. 1955;115:251-258.
73. Velisek L, Moshé SL, Xu SG, et al. Reduced susceptibility to seizures in carbonic anhydrase II deficient mutant mice. Epilepsy Res. 1993;14:115-121.
74. Masereel B, Rolin S, Abbate F, et al. Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002;45:312-320.
75. Woodbury DM. Pharmacology and mechanisms of action of antiepileptic drugs. In: Goldensohn ES, Appel SH, eds. Scientific Approaches to Clinical Neurology. Philadelphia, PA: Lea & Febiger; 1977:693-726.
76. Leniger T, Wiemann M, Bingmann D, et al. Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. Epilepsia. 2002;43:469-474.
77. Woodbury DM, Kemp JW. Basic mechanisms of seizures: neurophysiological and biochemical etiology. In: Shagass C, Gerson S, Friedhoff AJ, eds. Psychopathology and Brain Dysfunction. New York: Raven Press; 1977:149-182.
78. Woodbury DM. Antiepileptic drugs: carbonic anhydrase inhibitors. In: Glaser GH, Penry JK, Woodbury DM, eds. Antiepileptic Drugs: Mechanisms of Action. New York: Raven Press; 1980:617-634.
79. Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs. 2001;3:379-403.
80. Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia. 2001;42:746-749.
81. Resor SR, Jr, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology. 1990;40:1677-1681.
82. Katayama F, Miura H, Takanashi S. Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies. Brain Dev. 2002;24:150-154.
83. Reiss WG, Oles KS. Acetazolamide in the treatment of epilepsy. Ann Pharmacother. 1996;30:514-519.
84. Woodbury DM, Kemp JW. Other antiepileptic drugs: sulfonamides and derivatives. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989:855-876.
85. Kubota F, Kifune A, Shibata N, et al. Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: a quantitative digital radiography study. Epilepsy Res. 1999;33:93-97.
86. Futagi Y, Atani K, Abe J. Growth suppression in children receiving acetazolamide with antiepileptic drugs. Pediatr Neurol. 1996;15:323-326.
87. Bessey OA, Adam DJD, Hansen AE. Intake of vitamin B-6 and infantile convulsions: a first approximation of requirements of pyridoxine in infants. Pediatrics. 1957;10:33-44.
88. Livingston SJ, Hsu M, Petersen DC. Ineffectiveness of pyridoxine (vitamin B-6) in the treatment of epilepsy. Pediatrics. 1955;16:250-251.
89. Scriver CR. Vitamin B-6-dependency infantile convulsions. Pediatrics. 1960;26:62-74.
90. Scriver CR, Hutchison JH. The vitamin B-6 deficiency syndrome in human infancy: biochemical and clinical observations. Pediatrics. 1963;31:240-250.
91. Hunt AD, Stokes J, McCrory WW, et al. Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics. 1954;13:140-145.
92. Scriver CR, Whelan DT. Glutamic acid decarboxylase (GAD) in mammalian tissue outside the central nervous system, and its possible relevance to hereditary vitamin B-6 dependency with seizures. Ann N Y Acad Sci. 1969;166:83-96.
93. Bachmann DS. Late-onset pyridoxine-dependency convulsions. Ann Neurol. 1983;14:692-693.
94. Coker SB. Postneonatal vitamin B-6-dependent epilepsy. Pediatrics. 1992;90:221-223.
95. Kurleman G, Loscher W, Dominick HC, et al. Disappearance of neonatal seizures and low CSF GABA levels after treatment with vitamin B-6. Epilepsy Res. 1987;1:152-154.
96. Yoshida T, Tada K, Arakawa T. Vitamin B 6-dependency of glutamic acid decarboxylase in the kidney from a patient with vitamin B 6 dependent convulsion. Tohoku J Exp Med. 1971;104:195-198.
97. Baxter P. Pyridoxine-dependent seizures: a clinical and biochemical conundrum. Biochim Biophys Acta. 2003;1647:36-41.
98. Gospe SM. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol. 2002;26:181-185.
99. Bankier A, Turner M, Hopkins IJ. Pyridoxine dependent seizures: a wider clinical spectrum. Arch Dis Child. 1983;58:415-418.
100. Goutieres F, Aicardi J. Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants. Ann Neurol. 1985;17:117-120.
101. Mikati MA, Trevathan E, Krishnamoorthy KS, et al. Pyridoxine-dependent epilepsy: EEG investigations and long-term follow-up. Electroencephalogr Clin Neurophysiol. 1991;78:215-221.
102. Haenggeli CA, Girardin E, Paunier L. Pyridoxine-dependent seizures, clinical therapeutic aspects. Eur J Pediatr. 1991;150:452-455.
103. Gospe SM, Jr, Hecht ST. Longitudinal MRI findings in pyridoxinedependent seizures. Neurology. 1998;51:74-78.
104. Clarke TA, Saunders BS, Feldman B. Pyridoxine-dependent seizures requiring high doses of pyridoxine for control. Am J Dis Child. 1979;133: 963-965.
105. Krishnamoorthy KS. Pyridoxine-dependency seizure: report of a rare presentation. Ann Neurol. 1983;13:103-104.
106. Bass NE, Wyllie E, Cohen B, et al. Pyridoxine-dependent epilepsy: the need for repeated pyridoxine trials and the risk of severe electrocerebral suppression with intravenous pyridoxine infusion. J Child Neurol. 1996;11:422-424.
107. Lott IT, Coulombe T, DiPaolo RV, et al. Vitamin B 6-dependent seizures: pathology chemical findings in brain. Neurology. 1978;28:47-54.
108. Friedrich AM, Baumeister MD, Gsell W, et al. Glutamate in pyridoxinedependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. Pediatrics. 1994; 94:318-321.
109. Ito M, Mikawa M, Tangiguchi T. Cerebrospinal fluid GABA levels in children with infantile spasms. Neurology. 1984;34:235-238.
110. Loscher W, Siemes H. Cerebrospinal fluid: aminobutyric acid levels in children with different types of epilepsy: effect of anticonvulsant treatment. Epilepsia. 1985;16:314-319.
111. Blennow G, Starck L. High dose B-6 treatment in infantile spasms. Neuropediatrics. 1986;17:7-10.
112. Ito M, Okuno T, Hattori H, et al. Vitamin B-6 and valproic acid in treatment of infantile spasms. Pediatr Neurol. 1991;7:91-96.
113. Ohtsuka Y, Matsuda M, Kohno C, et al. Pyridoxal phosphate in the treatment of the West syndrome. In: Akimoto H, Seino M, Ward AA, Jr, eds. Advances in Epileptology. XIIIth Epilepsy International Symposium. New York: Raven Press; 1982:311-313.
114. Pietz J, Benninger C, Schafer H, et al. Treatment of infantile spasms with high-dosage vitamin B6. Epilepsia. 1993;34:757-763.
115. Jiao FY, Takuma Y, Wu S, et al. Randomized, controlled trial of high-dose intravenous pyridoxine in the treatment of recurrent seizures in children. Pediatr Neurol. 1997;17:54-57.
116. Wang HS, Kuo MF. Vitamin B6 related epilepsy during childhood. Chang Gung Med J. 2007;30(5):396-401.
117. Garty R, Yonis Z, Braham J, et al. Pyridoxine-dependent convulsions in an infant. Arch Dis Child. 1962;37:21-24.
118. Kroll J. Pyridoxine for neonatal seizures: an unexpected danger. Dev Med Child Neurol. 1985;27:369-382.
119. Heeley A, Puch RJP, Clayton BE, et al. Pyridoxol metabolism in vitamin B-6 responsive convulsions of early infancy. Arch Dis Child. 1978;53: 794-802.
120. Antopol W, Tarlov IM. Experimental study of the effects produced by large doses of vitamin B-6. J Neuropathol Exp Neurol. 1942;1:330-336.
121. Dalton K, Dalton JT. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand. 1987;76:8-11.
122. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985;35:1466-1468.
123. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse: a new megavitamin syndrome. N Engl J Med. 1983; 309:445-448.
124. Xu Y, Sladky JT, Brown MJ. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology. 1989;39:1077-1083.
125. Berger AR, Schaumburg HH, Schroeder C, et al. Dose response, coasting, and differential fibre vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology. 1992;42: 1367-1370.
126. Berger A, Schaumburg HH. More on neuropathy from pyridoxine abuse. N Engl J Med. 1984;311:986-987.
127. Albin R, Alpers JW, Greenberg HS, et al. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology. 1987;37:1729-1732.
128. Bernstein AL, Lobitz CS. A clinical and electrophysiologic study of the treatment of painful diabetic neuropathies with pyridoxine. In: Leklem JE, Reynolds RD, eds. Clinical and Physiological Applications of Vitamin B-6. Current Topics in Nutrition and Disease. New York: Alan R. Liss; 1988;19:415-423.
129. Del Tredici AM, Bernstein AL, Chinn K. Carpal tunnel syndrome and vitamin B-6 therapy. In: Reynolds RD, Leklem JE, eds. Vitamin B-6: Its Role in Health and Disease. Current Topics in Nutrition and Disease. New York: Alan R. Liss; 1985;13:459-462.
130. Reynolds RD. Pyridoxine dependent seizures. Arch Dis Child. 1984;59: 906-907.
131. Mpofu C, Alani SM, Whitehouse C, et al. No sensory neuropathy during pyridoxine treatment in homocystinuria. Arch Dis Child. 1991;66: 1081-1082.
132. McLachlan RS, Brown WF. Pyridoxine dependent epilepsy with iatrogenic sensory neuronopathy. Can J Neurol Sci. 1995;22:50-51.
133. Locock C. In discussion of Sieveking EH. Analysis of 52 cases of epilepsy observed by author. Lancet. 1857;1:527.
134. Palachios JM, Nieholt DL, Kuhar MJ. Ontogeny of GABA and benzodiazepine receptors: effects of Triton X-100, bromide and muscimol. Brain Res. 1979;179:390-395.
135. Woodbury DM, Pippenger CE. Bromides. In: Woodbury DM, Penry JK, Pippenger CE, eds. Antiepileptic Drugs. 2nd ed. New York: Raven Press; 1986:791-801.
136. Vaiseman N, Koren G, Pencharz P. Pharmacokinetics of oral and intravenous bromide in normal volunteers. Clin Toxicol. 1986;24:403-413.
137. Dreifuss FE. Bromides. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989:877-879.
138. Ernst J, Doose H, Baier WK. Bromides were effective in intractable epilepsy with generalized tonic-clonic seizures and onset in early childhood. Brain Dev. 1988;10:385-388.
139. Oguni H, Hayashi K, Oguni M, et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia. 1994;35:1140-1145.
140. Steinhoff BJ, Kruse R. Bromide treatment of pharmaco-resistant epilepsies with generalized tonic-clonic seizures: a clinical study. Brain Dev. 1992;14:144-149.
141. Stewart LS. Anticonvulsant medications. Emerg Med Serv. 2001;30:56-66.
142. James LP, Farrar HC, Griebel ML, et al. Bromism: intoxication from a rare anticonvulsant therapy. Pediatr Emerg Care. 1997;13:268-270.
143. Lichtenberg R, Zeller WP, Gatson R, et al. Bromate poisoning. J Pediatr. 1989;114:891-894.